CENTER VALLEY, Pa., (October 31, 2025) – Olympus Corporation has announced a voluntary, global medical device corrective action to provide further clarification on the safe and effective use of bronchoscopes with laser therapy, argon plasma coagulation or high-frequency cauterization equipment durin
Similar Posts
Healwell Homeo Private Limited – 706206 – 06/12/2025
CGMP/Finished Pharmaceuticals/AdulteratedCatheter Recall: Medline Industries Removes Reprocessed Electrophysiology and Ultrasound Catheters
Certain reprocessed catheters may contain residual particulates that could cause infection, embolism, or thrombosis.FDA Approves Labeling Changes to Menopausal Hormone Therapy Products
The U.S. Food and Drug Administration has approved drug labeling changes to six menopausal hormone therapy products, also known as hormone replacement therapy (HRT), to clarify risk considerations for these drugs.Recall Alert: Glycar SA Removes Pericardial Patch
Certain SJM Pericardial Patches from Glycar SA may not meet the required tensile strength specificationMacsen Drugs – 698202 – 03/05/2025
CGMP/Finished Pharmaceuticals/AdulteratedFDA approves belantamab mafodotin-blmf for relapsed or refractory multiple myeloma
On October 23, 2025, the Food and Drug Administration approved belantamab mafodotin-blmf (Blenrep, GlaxoSmithKline), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma who